Clinical bottom line
Adjunctive use of anti-oxidative agents in major depressive disorder (MDD) is an emerging area of interest, reflecting growing recognition of oxidative stress as a contributor to depression pathophysiology. Preliminary evidence suggests that targeting oxidative pathways may enhance antidepressant response in some patients, particularly those with treatment-resistant or inflammation-associated depression. However, current clinical data remain limited and heterogeneous, warranting cautious interpretation. Anti-oxidative adjuncts are not yet standard of care but represent a promising avenue for future personalized treatment strategies in MDD.
What the evidence shows
Major depressive disorder is increasingly understood as a multifactorial condition involving neuroinflammation and oxidative stress among other biological mechanisms (Yoosefian et al., 2026). Oxidative stress markers have been found elevated in subsets of patients with MDD, correlating with symptom severity and poor treatment response. This has spurred investigation into adjunctive therapies with anti-oxidative properties.
While direct clinical trials specifically evaluating anti-oxidative agents as adjuncts in MDD are sparse, the broader literature on pharmacological adjuncts highlights the potential for agents modulating oxidative pathways to improve outcomes. Yoosefian et al. (2026) review molecular mechanisms and novel therapeutics, noting that compounds with antioxidant effects may counteract neurobiological disruptions in MDD. This aligns with the rationale behind some adjunctive agents currently in clinical use or development, such as cariprazine and quetiapine, which exhibit indirect antioxidative and anti-inflammatory effects alongside their primary pharmacodynamics (Zarkowski et al., 2024; Bise et al., 2017).
Raison et al. (2016) discuss anti-inflammatory agents in MDD, highlighting the overlap between inflammation and oxidative stress pathways. Although their focus is on anti-inflammatory drugs, they emphasize that oxidative stress modulation is a complementary target that could enhance antidepressant efficacy, especially in patients with elevated inflammatory biomarkers. This suggests a subset of MDD patients might benefit most from adjunctive antioxidative strategies.
Preclinical and in vitro studies support the biological plausibility of antioxidative adjuncts. For example, Pin et al. (2018) characterize pharmacological profiles of novel compounds with potential adjunctive benefits, some of which may exert antioxidative effects. However, robust clinical trials specifically designed to test pure antioxidative agents in MDD remain lacking.
Caveats and uncertainty
The evidence for anti-oxidative agents as adjunctive treatments in MDD is largely indirect and hypothesis-generating rather than definitive. Most clinical data come from studies of agents with multiple mechanisms of action, making it difficult to isolate the contribution of antioxidative effects. The heterogeneity of MDD pathophysiology and patient populations complicates identification of who might benefit most.
Furthermore, clinical trials specifically targeting oxidative stress markers as primary outcomes are scarce. The field lacks large-scale, randomized controlled trials comparing adjunctive antioxidative agents to placebo or standard adjuncts. Biomarker-guided approaches to select patients with oxidative stress-driven depression have not yet been validated in routine practice.
Safety and tolerability profiles of putative antioxidative adjuncts also require careful evaluation, especially given the polypharmacy common in treatment-resistant MDD. Potential interactions with standard antidepressants and long-term effects remain underexplored.
How this may change practice
Currently, the use of anti-oxidative agents as adjunctive treatment in MDD should be considered experimental and primarily confined to research settings or carefully selected clinical cases. Clinicians should remain informed about ongoing developments and emerging evidence, particularly regarding biomarker-guided personalized treatment.
Incorporating oxidative stress assessment into clinical evaluation may become feasible with advances in biomarker technology, potentially enabling targeted adjunctive therapies. Future practice may involve stratifying patients based on oxidative and inflammatory profiles to optimize adjunctive treatment choices.
Until more definitive evidence emerges, clinicians should continue to rely on established adjunctive treatments with robust efficacy data, such as certain atypical antipsychotics (e.g., cariprazine, quetiapine) and consider antioxidative strategies as part of a broader integrative approach that includes lifestyle modifications known to reduce oxidative stress.